SiRNA mediated knockdown of fibroblast growth factor receptors 1 or 3 inhibits FGF-induced anchorage-independent clonogenicity but does not affect MAPK activation

Oncology Reports

Volumn 15, Issue 6, 2006, Pages 1407-1416

  Estes II, Norman R ^a   Thottassery, Jaideep V ^a   Kern, Francis G ^b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

Fibroblast growth factor receptor; RNA interference; Signal transduction; Small interfering RNA

Indexed keywords

FGF4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; RECOMBINANT PROTEIN; SMALL INTERFERING RNA;

ADRENAL CORTEX TUMOR; ARTICLE; DOWN REGULATION; DRUG ANTAGONISM; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ADRENAL CORTEX NEOPLASMS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 39049192615     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Basilico C and Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115-165, 1992.
2. Galzie Z, Kinsella AR and Smith JA: Fibroblast growth factors and their receptors. Biochem Cell Biol 75: 669-685, 1997. (Pubitemid 127733222)
3. Bottcher RT and Niehrs C: Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26: 63-77, 2005. (Pubitemid 40209387)
4. Powers CJ, McLeskey SW and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr-Relat Cancer 7: 165-197, 2000.
5. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA and Donoghue DJ: Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19: 3309-3320, 2000. (Pubitemid 30487417)
6. Cappellen D, De Oliveira C, Ricol D, et al: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20, 1999.
7. Jang JH, Shin KH and Park JG: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61: 3541-3543, 2001.
8. Yoshimura N, Sano H, Hashiramoto A, et al: The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol 89: 28-34, 1998. (Pubitemid 28457883)
9. Onose H, Emoto N, Sugihara H, Shimizu K and Wakabayashi I: Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur J Endocrinol 140: 169-173, 1999. (Pubitemid 29090447)
10. Yamaguchi F, Saya H, Bruner JM and Morrison RS: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91: 484-488, 1994. (Pubitemid 24041426)
11. Shah RN, Ibbitt JC, Alitalo K and Hurst HC: FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. Oncogene 21: 8251-8261, 2002. (Pubitemid 35477865)
12. Cavallaro U, Niedermeyer J, Fuxa M and Christofori G: N-CAM modulates tumour-cell adhesion to matrix by inducing FGFreceptor signalling. Nat Cell Biol 3: 650-657, 2001. (Pubitemid 32624421)
13. Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB and Kern FG: Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and lacZ. Cancer Res 53: 2178-2187, 1993. (Pubitemid 23145745)
14. Zhang L, Kharbanda S, Chen D, et al: MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 15: 2093-2108, 1997. (Pubitemid 27489136)
15. McLeskey SW, Zhang L, El-Ashry D, et al: Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. Clin Cancer Res 4: 697-711, 1998. (Pubitemid 28193571)
16. Zhang L, Kharbanda S, Hanfelt J and Kern FG: Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res 58: 352-361, 1998. (Pubitemid 28047079)
17. Halper J and Moses HL: Epithelial tissue-derived growth factor-like polypeptides. Cancer Res 43: 1972-1979, 1983. (Pubitemid 13088725)
18. Fang W, Hartmann N, Chow DT, Riegel AT and Wellstein A: Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem 267: 25889-25897, 1992. (Pubitemid 23013992)
19. Shin SI, Freedman VH, Risser R and Pollack R: Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435-4439, 1975.
20. Ussar S and Voss T: MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem 279: 43861-43869, 2004. (Pubitemid 39390693)
21. Leibovitz A, McCombs WBI, Johnston D, McCoy CE and Stinson JC: New human cancer cell culture lines. I.SW-13, small-cell carcinoma of the adrenal cortex. J Natl Cancer Inst 51: 691-697, 1973.
22. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: E45, 2001.
23. Wellstein A, Lupu R, Zugmaier G, et al : Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1: 63-71, 1990.
24. Goldfarb M: Signaling by fibroblast growth factors: the inside story. Sci STKE 2001: E37, 2001.
25. Wellstein A, Zugmaier G, Califano JA 3rd, Kern F, Paik S and Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 83: 716-720, 1991.
26. Dickson RB and Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8: 29-43, 1987.
27. Boden D, Pusch O, Silbermann R, Lee F, Tucker L and Ramratnam B: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 32: 1154-1158, 2004. (Pubitemid 38854717)
28. Kim MS, Kim CJ, Jung HS, et al : Fibroblast growth factor 2 induces differentiation and apoptosis of Askin tumour cells. J Pathol 202: 103-112, 2004. (Pubitemid 38072851)
29. Deo DD, Axelrad TW, Robert EG, Marcheselli V, Bazan NG and Hunt JD: Phosphorylation of STAT-3 in response to basic fibroblast growth ractor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J Biol Chem 277: 21237-21245, 2002. (Pubitemid 34952260)
30. Hart KC, Robertson SC and Donoghue DJ: Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 12: 931-942, 2001. (Pubitemid 33051989)
31. Zhu L, Somlo G, Zhou B, et al : Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 4: 787-798, 2005. (Pubitemid 40767123)
32. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267, 1998.
33. Gysin S, Lee SH, Dean NM and McMahon M: Pharmacologic inhibition of RAF→MEK→ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 65: 4870-4880, 2005. (Pubitemid 40740826)
34. Brown JW, Cappell S, Perez-Stable C and Fishman LM: Extracts from two marine sponges lower cyclin B1 levels cause a G2/M cell cycle block and trigger apoptosis in SW-13 human adrenal carcinoma cells. Toxicon 43: 841-846, 2004. (Pubitemid 38992531)
35. Brown JW, Kesler CT, Neary JT and Fishman LM: Effects of marine sponge extracts on mitogen-activated protein kinase [MAPK/ERK(1,2)] activity in SW-13 human adrenal carcinoma cells. Toxicon 39: 1835-1839, 2001. (Pubitemid 32971822)
36. Schwartz MA: Integrins, oncogenes, and anchorage independence. J Cell Biol 139: 575-578, 1997. (Pubitemid 27485824)
37. Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 13: 555-562, 2001. (Pubitemid 32817013)
38. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
39. Zeng Q, Chen S, You Z, et al: Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem 277: 25203-25208, 2002. (Pubitemid 34951827)
40. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH and Downward J: Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16: 2783-2793, 1997. (Pubitemid 27226215)
41. McFall A, Ulku A, Lambert QT, Kusa A, Rogers-Graham K and Der CJ: Oncogenic ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol 21: 5488-5499, 2001. (Pubitemid 32702453)